Sort
48,018 grants matching “immunotherapy”
VLA-4âtargeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapy
$611,562Ravi Bhasker Patel · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA
IDENTIFYING NOVEL IMMUNE EVASION TUMOR IMMUNE NETWORKS AS TARGETS FOR CCRCC IMMUNOTHERAPY
$611,415University Health Network · · FY2022 · Defense Health Agency
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
$611,350Estuardo Aguilar-Cordova · Advantagene, Inc · R44 · FY2020 · CA
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
$611,350Estuardo Aguilar-Cordova · Advantagene, Inc · R44 · FY2021 · CA
Targeting physical stress-driven mechanisms to overcome glioblastoma treatment resistance
$611,308Lance L Munn · Massachusetts General Hospital · U01 · FY2022 · CA
Targeting physical stress-driven mechanisms to overcome glioblastoma treatment resistance
$611,307Lance L Munn · Massachusetts General Hospital · U01 · FY2023 · CA
Actionable categories of avoidable hospital care among adults with cancer
$611,294Arthur Seokjae Hong · Ut Southwestern Medical Center · R01 · FY2023 · CA
New generation of long acting nucleos(t)ides and immune stimulant for treatment of chronic hepatitis B
$611,174Larisa Y Poluektova · University Of Nebraska Medical Center · R01 · FY2023 · AI
New generation of long acting nucleos(t)ides and immune stimulant for treatment of chronic hepatitis B
$611,174Larisa Y Poluektova · University Of Nebraska Medical Center · R01 · FY2024 · AI
New generation of long acting nucleos(t)ides and immune stimulant for treatment of chronic hepatitis B
$611,174Natalia Aleksandr Osna · University Of Nebraska Medical Center · R01 · FY2025 · AI
Microfluidic isolation and molecular analysis of circulating tumor cells for the study of neuroendocrine transdifferentiation in prostate cancer
$611,138Mehmet Toner · Massachusetts General Hospital · U01 · FY2022 · CA
POTENTIATION OF ANTI-TUMOR IMMUNITY BY ONCOLYTIC VIRUS IN SITU VACCINATION
$611,086Dmitriy Zamarin · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · CA
Development and Evaluation of Advanced Non-Contrast Perfusion MRI for Monitoring Treatment Response in Brain Metastases
$611,040Qin Qin · Johns Hopkins University · R01 · FY2024 · CA
Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy
$611,011Mary L. Disis · University Of Washington · R01 · FY2012 · CA
Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy
$610,938Donald Ym Leung · National Jewish Health · U01 · FY2022 · AR
Impact of ART on DC and Teg Responses in Oral Tissues
$610,937Melissa J Robbiani · Population Council · R01 · FY2009 · DE
Exploring CD38 molecular biology and imaging in multiple myeloma pathogenesis
$610,920Monica Shokeen · Washington University · R01 · FY2023 · CA
Exploring CD38 molecular biology and imaging in multiple myeloma pathogenesis
$610,920Monica Shokeen · Washington University · R01 · FY2022 · CA
Engineering of pan-neutralizing anti-HIV envelope antibodies
$610,897Mohammad Mohseni Sajadi · University Of Maryland Baltimore · R01 · FY2020 · AI
Radiation and dendritic cell combination to improve immunotherapy response in intrahepatic cholangiocarcinoma
$610,890Sean S Park · Mayo Clinic Rochester · R01 · FY2025 · CA
Radiation and dendritic cell combination to improve immunotherapy response in intrahepatic cholangiocarcinoma
$610,890Sean S Park · Mayo Clinic Rochester · R01 · FY2024 · CA
Regulation of ACAID by lymphocytes with NK markers
$610,866Joan Stein-Streilein · Schepens Eye Research Institute · R01 · FY2009 · EY
Personalized Cancer Therapy Guided by Photoacoustic Chemical Imaging (PACI) of Tumor Microenvironment (TME)
$610,845Xueding Wang · University Of Michigan At Ann Arbor · R01 · FY2022 · CA
Quantitative assessment of pre-metastatic immune subversion as a risk factor for melanoma relapse
$610,829Svetomir Nenad Markovic · Mayo Clinic Rochester · R01 · FY2023 · CA
Bottlebrush polymer prodrugs for targeted delivery of combination therapies and in vivo imaging of pharmacological response
$610,792Jeremiah Allen Johnson · Massachusetts Institute Of Technology · R01 · FY2023 · CA